Sanofi acquires rights to develop and commercialize Aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Subscribe To Our Newsletter & Stay Updated